Popular terms

Antibodies topics
Antibodies
Recombinant
Nucleic Acid
Nucleic Acids
Polypeptide
Therapeutics
Immunoglobulin
Immunoglobulins
Monoclonal
Radiation Therapy
Desmoplastic
Hypertension
Hypertensive
Immunotherapy
Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibodies patents



      

This page is updated frequently with new Antibodies-related patent applications.




Date/App# patent app List of recent Antibodies-related patents
05/26/16
20160146844 
 Compositions and methods for binding lysophosphatidic acid patent thumbnailnew patent Compositions and methods for binding lysophosphatidic acid
Compositions and methods for making and using anti-lpa agents, for example, monoclonal antibodies, are described.. .
Lpath, Inc.


05/26/16
20160146840 
 Augurin immunoassay patent thumbnailnew patent Augurin immunoassay
The present invention relates to an immunoassay method for the detection of augurin or a precursor or fragment thereof comprising contacting a sample suspected of comprising augurin or a precursor or fragment thereof with a first and second antibody specific for augurin or a precursor or fragment thereof, wherein said first and second antibodies or antigen-binding fragments or derivatives thereof are specific for epitopes comprised in the sequence spanning amino acids 71 to 107 of pre-augurin according to seq id no:1.. .
B.r.a.h.m.s Gmbh


05/26/16
20160146831 
 Antibody and cytokine biomarker profiling for determination of patient responsiveness patent thumbnailnew patent Antibody and cytokine biomarker profiling for determination of patient responsiveness
Compositions and methods are provided for prognostic classification of autoimmune disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of circulating blood levels of serum autoantibodies and/or cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness.
The Board Of Trustees Of The Leland Stanford Junior University


05/26/16
20160146830 
 Proteomic identification of antibodies patent thumbnailnew patent Proteomic identification of antibodies
Methods and compositions for identification of candidate antigen-specific variable regions as well as generation of antibodies or antigen-binding fragments that could have desired antigen specificity are provided. For example, in certain aspects, methods for determining amino acid sequences of serum antibody cdr3 and abundancy levels are described.
Board Of Regents, The University Of Texas System


05/26/16
20160146829 
 Methods for detecting antibodies patent thumbnailnew patent Methods for detecting antibodies
Methods for detection of any antibody utilizing a standardized approach applicable to any antibody which provides highly specific assays specific for individual or multiple antibodies. The methods enable improved pharmacokinetic analysis during development and clinical use of antibody-based therapies as well as determination of diagnostic and/or prognostic factors..
The Regents Of The University Of California


05/26/16
20160146825 
 Method for detecting low concentrations of specific cell from high concentrations of cell populations, and  collecting and analyzing detected cell patent thumbnailnew patent Method for detecting low concentrations of specific cell from high concentrations of cell populations, and collecting and analyzing detected cell
Conventional ctc detection methods have been problematic in that 1) there is no technique for automatically determining and counting live ctcs in a brief period of time, 2) no process has been developed for detecting, counting, and thereafter collecting and culturing live ctcs, and 3) there exists no flow cytometer that is contamination free and is capable of measuring an entire sample. Provided is a ctc detection method which comprises a pre-treatment step for concentrating and fluorescence staining ctcs, and a step for identifying and counting ctcs.
On-chip Biotechnologies Co., Ltd.


05/26/16
20160146824 
 Diagnostic assays and kits for detection of folate receptor 1 patent thumbnailnew patent Diagnostic assays and kits for detection of folate receptor 1
The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided..
Immunogen, Inc.


05/26/16
20160146811 
 Ompa and asp14 in vaccine compositions and as diagnostic targets patent thumbnailnew patent Ompa and asp14 in vaccine compositions and as diagnostic targets
Anaplasma phagocytophilum surface proteins asp14 and ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Asp14 and/or ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response.
Virginia Commonwealth University


05/26/16
20160146809 
 Peptides and methods for the detection of leishmaniasis patent thumbnailnew patent Peptides and methods for the detection of leishmaniasis
The present invention relates to peptides and methods for the detection of anti-leishmanial antibodies in individuals suspected of infection with the protozoan parasite of the genus leishmania, especially infection with a south american strain causing the american tegumentary leishmaniasis (atl).. .
Universidad Peruana Cayetano Heredia


05/26/16
20160146804 
 Dna-conjugated antibodies for improved antibody affinity and reduced antibody cross reactivity patent thumbnailnew patent Dna-conjugated antibodies for improved antibody affinity and reduced antibody cross reactivity
Disclosed are specific binding molecules (e.g. antibodies) that are provided in a set of conjugates, where each conjugate comprises an antibody linked to an oligonucleotide (oligo), such as a dna oligonucleotide.
The Board Of Trustees Of The Leland Stanford Junior University


05/26/16
20160145627 
new patent

Rna interference-based therapeutic against anthrax


The present invention includes sirnas and antibodies that block the interaction between tem8 and/or cmg2 cell surface proteins and anthrax toxin and methods of treating anthrax exposure with the same.. .
Texas Tech University System


05/26/16
20160145355 
new patent

Bispecific antibodies


The present invention provides, inter alia, bispecific antibodies containing a first antigen binding moiety that specifically binds an epitope on human cytotoxic t-lymphocyte-associated antigen 4 (ctla-4) and a second antigen binding moiety that specifically binds an epitope on a human programmed death 1 (pd-1) receptor. Also provided are pharmaceutical compositions containing such bispecific antibodies, as well as methods and kits for treating cancer using such bispecific antibodies and pharmaceutical compositions..
Biomed Valley Discoveries, Inc.


05/26/16
20160145351 
new patent

Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof


The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
Amgen Inc.


05/26/16
20160145350 
new patent

Antibodies against cd73 and uses thereof


The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human cluster of differentiation 73 (cd73) with high affinity, and inhibit the activity of cd73, and optionally mediate antibody dependent cd73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Bristol-myers Squibb Company


05/26/16
20160145349 
new patent

Humanized anti-factor d antibodies and uses thereof


The invention relates to anti-factor d antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease..
Genentech, Inc.


05/26/16
20160145347 
new patent

Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer


Disclosed herein are antibodies that detect a lipid-like antigen on prostate cancer cells and methods of detecting and treating prostate cancer using the same.. .
The Trustees Of The University Of Pennsylvania


05/26/16
20160145345 
new patent

Human anti-b7rp1 neutralizing antibodies


This invention provides antibodies that interact with or bind to human b7 related protein-1 (b7rp1) and antibodies that bind to and neutralize the function of b7rp1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing b7rp1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-b7rp1 antibodies.
E. R. Squibb & Sons, L.l.c.


05/26/16
20160145344 
new patent

Murine and human innate lymphoid cells and lung inflammation


Described herein are methods and compositions for treatment of inflammation, such as inflammation in lung and/or airway tissue, including asthma innate lymphoid cells (ilcs), such as type 2 ilc2s, are herein described as capable of il-33 signaling activation, leading to airway hyperresponsiveness (ahr) and inflammation. Further described is the hereto unknown discovery that icos-ligand is expressed in ilc2s, that icos binding of icos to icos-ligand is required for its function in ilc2s, and that while il-33 treatment induces ahr in control mice, il-33 cannot induce ahr in mice receiving treatment via anti-icos-ligand antibodies.
University Of Southern California


05/26/16
20160145343 
new patent

Anti-mucin 1 binding agents and uses thereof


This disclosure provides anti-muc1 binding agents (e.g., antibodies and chimeric antigen receptors) and methods of treatment, prophylaxis, detection, and diagnosis using the same.. .
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


05/26/16
20160145342 
new patent

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof


Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible tnf receptor (gitr). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer.
Bristol-myers Squibb Company


05/26/16
20160145341 
new patent

Antibody formulation


Anti-baffr antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid..
Novartis Ag


05/26/16
20160145339 
new patent

Construction and application of bispecific antibody her2xcd3


The present invention provides a bispecific antibody. The bispecific antibody provided by the present invention comprises a single-chain unit and a monovalent unit, wherein the single-chain unit has a specific binding capability against a surface antigen cd3 of an immune cell; the monovalent unit has a specific binding capability against a surface antigen her2 of a tumor cell; the single-chain unit comprises a single-chain variable fragment scfv fused with an fc fragment; and the monovalent unit comprises a light chain and heavy chain pair.
Wuhan Yzy Biopharma Co., Ltd.


05/26/16
20160145338 
new patent

Human monoclonal antibodies specific for cd22


Disclosed herein are isolated human monoclonal antibodies that specifically bind human cd22 with a dissociation constant (kd) of 25 nm or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed.
The Government Of The United States Of America As Represented By The Secretary Of The Department Of


05/26/16
20160145336 
new patent

Effector-deficient anti-cd32a antibodies


Effector-deficient anti-cd32a monoclonal antibodies are encompassed, as are method and uses for treating cd32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.. .
Adventist Health System/sunbelt Inc.


05/26/16
20160145335 
new patent

Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease


The present invention provides chimeric and humanized versions of anti-cd19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human cd19 antigen and that may mediate adcc, cdc, and/or apoptosis for the treatment of b cell diseases and disorders, such as, but not limited to, b cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (gvhd), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients..
Medimmune, Llc


05/26/16
20160145334 
new patent

Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof


The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the nogo-66 receptor and neutralize the nogo-66 receptor.
Abbvie Inc.


05/26/16
20160145333 
new patent

Cb-1 receptor antigen-binding proteins and uses thereof


This disclosure relates to cb1 receptor antigen-binding proteins, e.g. antibodies and methods of using the cb1 receptor antibodies.
Amgen Inc.


05/26/16
20160145332 
new patent

Il-21 binding proteins and uses thereof


The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-21 (il-21) and uses thereof, e.g., in therapy.. .
Monash University


05/26/16
20160145326 
new patent

Angiopoietin-like 4 antibodies and methods of use


The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “angptl4”), and pharmaceutical compositions and methods of treatment comprising the same.. .
Novartis Ag


05/26/16
20160145325 
new patent

Agrochemical compositions comprising antibodies binding to sphingolipids


The present invention relates to agrochemical and biological control compositions for combating pests, more specifically plant pests, comprising at least one heavy chain variable domain of an antibody, which specifically binds to a sphingolipid of a plant pathogen. The invention further provides methods for protecting or treating a plant or a part of a plant from an infection or other biological interaction with a plant pathogen, at least comprising the step of applying directly or indirectly to a plant or to a part of a plant, an agrochemical composition, under conditions effective to protect or treat a plant or a part of a plant against a infection or biological interaction with a plant pathogen.
Agrosavfe N.v.


05/26/16
20160145324 
new patent

Antibodies directed to bacillus anthracis protective antigen


This disclosure generally relates to therapeutic antibodies for treating bacillus anthracis (b. Anthracis) infection, to specific variants thereof, pharmaceutical composition comprising them and to methods for their use..

05/26/16
20160145323 
new patent

Antibodies against chikungunya virus and uses thereof


Embodiments disclosed herein provide for antibodies, including neutralizing antibodies, against chikungunya virus, uses thereof, and methods of identifying antibodies, including neutralizing antibodies, against chikungunya virus. In some embodiments, antibodies that binds to a chikv antigen, wherein the antigen is the chikv e1, e2, e3 protein, or any heterocomplex thereof are provided.
Blood Systems Research Institute


05/26/16
20160145322 
new patent

Human antibodies binding to rsv g proteins


The disclosure provides isolated antibodies and antigen-binding fragments that bind to the g protein of rsv and which are capable of neutralizing rsv.. .
Crucell Holland B. V.


05/26/16
20160145321 
new patent

Human antibodies binding to rsv g protein


The disclosure relates to isolated antibodies and antigen-binding fragments that bind to the g protein of rsv and which are capable of neutralizing rsv a and b subtypes, and the use thereof in the diagnosis, prophylaxis, and/or treatment of rsv infections.. .
Crucell Holland B.v.


05/26/16
20160145320 
new patent

Broad-spectrum monoclonal antibody recognizing ha1 domain of hemagglutinin of influenza virus


The invention relates to antibodies recognizing epitopes on ha1 domain of hemagglutinin (ha) protein of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to ha1 domain of different ha subtypes and specifically bind to ha1 domain of hemagglutinin (ha) protein of h1 subtype (including seasonal h1n1 and 2009 pandemic h1n1) and h5 subtype of influenza viruses.
Xiamen University


05/26/16
20160145319 
new patent

Human cytomegalovirus neutralizing antibodies and use thereof


The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hcmv, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hcmv gene ul products. The invention also relates to immortalized b cells that produce, and to epitopes that bind to, such antibodies and antibody fragments.
Institute For Research In Biomedicine


05/26/16
20160145290 
new patent

E-selectin antagonist compounds, compositions, and methods of use


Methods and compositions using e-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of e-selectin to an e-selectin ligand. Described herein are e-selection antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation..
Glycomimetics, Inc.


05/26/16
20160144042 
new patent

Design and development of masked therapeutic antibodies to limit off-target effects


In one embodiment, a masked monoclonal antibody (mab) is provided, the mab, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mab) is provided, which includes a therapeutic mab and a mask, the mask comprising protein a and protein l attached by a protease cleavable linker..
City Of Hope


05/26/16
20160144029 
new patent

Anti-erbb3 antibodies and uses thereof


The present invention provides antibodies that bind to erbb3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human erbb3.
Regeneron Pharmaceuticals, Inc.


05/26/16
20160144020 
new patent

Johnson grass allergenic pollen proteins, encoding nucleic acids and methods of use


Allergenic johnson grass proteins, antibodies thereto and encoding nucleic acids are provided, which may be used for the diagnosis and/or therapy of sensitivity to these allergenic proteins or to immunologically cross-reactive allergenic proteins. In particular, the allergenic johnson grass proteins and nucleic acids may be used for environmental testing for airborne allergens and/or for batch standardization of diagnostic and therapeutic compositions..
Queensland University Of Technology


05/26/16
20160144019 
new patent

Novel therapeutic and diagnostic means


Disclosed is a method for treatment of hiv related diseases comprising targeting complexes between on the one hand the c5 domain of gp120 and on the other hand gp41 or the c2 domain of gp120. The complexes may be stabilised by administering compounds, such as antibodies, capable of directly interacting with and stabilising the complex, or by immunizing with c5 and gp41/c2 derived material so as to induce antibodies that bind to and stabilise the complex..
Bionor Immuno As


05/26/16
20160144016 
new patent

Synthetic oligosaccharides for p. aeruginosa vaccine


The present invention provides synthetic pseudomonas aeruginosa lipooligosaccharide (los)-based oligosaccharides and conjugates containing various p. Aeruginosa serotype-specific oligosaccharide antigens or various core p.
Synglyco Pharmaceuticals, Inc.


05/26/16
20160144015 
new patent

Bordetella outer-membrane protein antigens and methods of making and using the same


An isolated protein or peptide selected from the group consisting of bordetella colonization factor a (bcfa) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.. .
Wake Forest University Health Sciences


05/26/16
20160143866 
new patent

Combination therapy for administration of monoclonal antibodies


A combination therapy is disclosed for the treatment of a patient, such as a human, with a monoclonal antibody. The methods can include administering to a patient a monoclonal antibody, for example, a tnt-alpha inhibitor such as adalimumab, certolizumab pegol, golimumab, and infliximab; and administering to the patient colchicine.

05/19/16
20160139144 

Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase


Provided herein are methods of detecting the presence of a pegylated enzyme, an enzyme-specific antibody (e.g., a neutralizing antibody or of a particular isotype), or a polyethylene glycol (peg)-specific antibody in a sample, such as a bodily fluid or tissue of a patient. In certain embodiments, the enzyme is phenylalanine ammonia-lyase (pal), such as anabaena variabilis (av) pal administered to the patient as part of an enzyme substitution therapy for diseases or disorders, such as phenylketonuria (pku), or cancer therapy..
Biomarin Pharmaceutical Inc.


05/19/16
20160139135 

Optically-detectable enzyme substrates and their use


The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a β-lactamase in a sample.
Life Technologies Corporation


05/19/16
20160139131 

Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same


The present invention provides novel antibodies specifically bind to an epitope on cd43 and cea expressed on nonhematopoietic cancer cells, but do not specifically bind to a cd43 expressed by a leukocyte or by a jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a lea structure, a lea-lactose structure, a lndfh ii structure, or a lnt structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes..
Bioalliance C.v.


05/19/16
20160139130 

Detecting cancer with anti-cxcl16 and anti-cxcr6 antibodies


Methods for detecting cancer or monitoring cancer progression in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers.
Jyant Technologies, Inc.


05/19/16
20160139119 

Method of detecting the presence or absence of autoantibodies


The invention relates to methods of detecting the presence or absence of autoantibodies in an individual and to related methods and kits.. .
Isis Innovation Limited


05/19/16
20160138002 

Antibody-urease conjugates


This disclosure provides antibody-urease conjugates having therapeutic and diagnostic utility. More specifically, the disclosure relates to diagnostic and/or therapeutic conjugates that are prepared by conjugating one or more whole antibodies to ease..
Helix Biopharma Corp.


05/19/16
20160137750 

Method of treating a pathological syndrome


A method of treating disorder or condition that relates to intracellular signal transmission of a neurotransmitter, comprising administration of an homeopathically potentized form of antibodies to an antigen, which antigen is a molecule capable of effecting the intracellular signal transmission of a neuroreceptor, in particular dopamine or serotonin.. .

05/19/16
20160137747 

Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity


The invention relates to antibodies against human cd39 and use thereof for inhibiting t regulatory cells (treg) activity. More particularly cd39 antibodies may be used for the treatment or prevention of cancers and infectious diseases..
Inserm (institut National De La Sante Et De La Recherche Medicale)


05/19/16
20160137743 

Glycan-interacting compounds


The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them..
Siamab Therapeutics, Inc.


05/19/16
20160137740 

Humanized anti-ox40 antibodies and uses thereof


The disclosure provides humanized anti-ox40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer..
Medimmune, Llc


05/19/16
20160137739 

Oncostatin m receptor antigen binding proteins


The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins. E.g., antibodies and functional fragments, derivatives, muteins, and variants thereof.
Biogen Ma Inc.


05/19/16
20160137738 

Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies


Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human igf-1r and human erbb3. Exemplary antibodies inhibit signal transduction through either or both of igf-1r and erbb3.
Merrimack Pharmaceuticals, Inc.


05/19/16
20160137737 

Integrin alpha-v beta8 neutralizing antibody


The present invention relates to αvβ8 antagonists, anti-αvβ8 antibodies or immunoconjugates for reducing tgfβ activation in an individual. Further provided are compositions comprising one of the αvβ8 antagonists, anti-αvβ8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter..
The Regents Of The University Of California


05/19/16
20160137735 

Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies


Compositions and methods for treating mm are provided herein.. .
Dana-farber Cancer Insitute, Inc.


05/19/16
20160137734 

Therapeutic cd47 antibodies


Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, cd47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to cd47. Also provided are combinations of any of the foregoing.
Vasculox Inc.


05/19/16
20160137733 

Therapeutic cd47 antibodies


Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, cd47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to cd47. Also provided are combinations of any of the foregoing.
Vasculox Inc.


05/19/16
20160137731 

Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor


The present invention is based, in part, on the identification of novel human anti-pd-1, pd-l1, and pd-l2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating pd-1, pd-l1, and/or pd-l2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-pd-1, pd-l1, and pd-l2 antibodies described herein..
Emory University


05/19/16
20160137730 

Antibody drug conjugates


This application discloses anti-p-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates.
Novartis Ag


05/19/16
20160137729 

Anti cd37 antibodies


Chimeric and humanized anti-cd37 antibodies and pharmaceutical compositions containing them are useful for the treatment of b cell malignancies and autoimmune and inflammatory diseases that involve b cells in their pathology.. .
Boehringer Ingelheim International Gmbh


05/19/16
20160137728 

Antibody specifically binding to insulin-like growth factor-1


Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (seq id no:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample..
Roche Diagnostics Operations, Inc.


05/19/16
20160137725 

Methylation and acetylation sites


The disclosure features over 5000 methylation and acetylation sites identified in human cell line, human serum and mouse tissues, peptides (including aqua peptides) comprising a methylation or acetylation site of the disclosure, antibodies specifically bind to a methylation or acetylation site of the disclosure, and diagnostic and therapeutic uses of the above.. .
Cell Signaling Technology, Inc.


05/19/16
20160137724 

Antibodies for prevention and treatment of diseases caused by clostridium difficile


The present invention relates to an antibody having specificity for an immunogenic determinant consisting of the pentasaccharide repeating unit of the clostridium difficile glycopolymer ps-i: α-l-rhap-(1→3)-β-d-glcp-(1→4)-[α-l-rhap-(1→3)]-α-d-glcp-(1→2)-α-d-glcp or a fragment thereof. Said antibody is able to prevent and treat diseases caused by c.
Max-planck-gesellschaft Zur Foerderung Der Wissenschaften E.v.


05/19/16
20160137723 

Monoclonal antibodies that react with the capsule of bacillus anthracis


The present disclosure relates to monoclonal antibodies that bind poly-γ-d-glutamic acid (γdpga), which is present on the surface of bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof.
The United States Of America, As Represented By The Secretary, Department Of Health And Human


05/19/16
20160137722 

Humanized monoclonal antibodies that specifically bind and/or neutralize japanese encephalitis virus (jev) and their use


Disclosed herein are isolated humanized monoclonal antibodies that specifically bind japanese encephalitis virus (jev) with a binding affinity of about 1.0 nm or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed.
The United States Of America, As Represented By The Secretary, Department Of Health And Human


05/19/16
20160137721 

Antibodies against influenza virus hemagglutinin and uses thereof


Provided herein are antibodies that cross-react with hemagglutinin from strains of influenza virus of the same subtype or different subtypes, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that cross-react with hemagglutinin from strains of influenza virus of the same subtype or different subtypes and methods of using such antibodies to diagnose, prevent or treat influenza virus disease..
Icahn School Of Medicine At Mount Sinai


05/19/16
20160137705 

Colon disease targets and uses thereof


The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (ccat) and antibodies binds to ccat.
Celera Corporation


05/19/16
20160137702 

Gas57 mutant antigens and gas57 antibodies


The invention provides mutants of gas57 (spy0416) which are unable to cleave il-8 and similar substrates but which still maintain the ability to induce protection against s. Pyogenes.
Glaxosmithkline Biologicals S.a.


05/19/16
20160136310 

Systems, compositions, and methods for local imaging and treatment of pain


Pain factors are labeled with targeted agents or markers delivered into the body. The labeled pain factors are imaged with appropriate imaging tools in a manner allowing selective identification and localization of areas of pain source or transmission.
The Regents Of The University Of California


05/19/16
20160136299 

Glycoengineered antibody drug conjugates


The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
Genzyme Corporation


05/19/16
20160136297 

Targeting abcb5 for cancer therapy


The invention relates to methods for treating a subject by manipulating abcb5 on a cell as well as related products. The methods include methods of treating cancer using abcb5 binding molecules such as antibodies and fragments thereof..
The Brigham And Women's Hospital, Inc


05/19/16
20160136296 

Methods of making dll3 antibody drug conjugates


Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. .
Stemcentrx, Inc.


05/19/16
20160136288 

Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent


The application relates to an immunogenic composition comprising a continuous aqueous phase and at least two dispersed phases 1 and 2 as droplets, wherein the dispersed phase 1 comprises a surfactant 1 bearing an antigen and the dispersed phase 2 comprises an immunostimulating agent 2, to its preparation method and its uses, notably for producing antibodies, as a drug, as a vaccine or in an immunization method.. .
Institut National De La Sante Et De La Recherche Medicale


05/12/16
20160132634 

Computer-implemented methods of determining protein viscosity


The invention provides computer-implemented methods for screening proteins such as antibodies based on viscosity properties. The methods involve making a spatial charge map (scm) of the three-dimensional structure of the antibody or protein and determine a scm score depending on a condition such as e.g.
Novartis Pharma Ag


05/12/16
20160132633 

Methods and systems for predicting misfolded protein epitopes


A method and system to identify an epitope unique to a misfolded form of a protein is provided. Sets of one or more amino acid residues are selected from a model representing the structure of the protein; the free energy of unfolding of each set is determined; and the epitope is identified from the sets having a total probability of unfolding above a minimum probability or a free energy of unfolding below a minimum energy.
The University Of British Columbia


05/12/16
20160132631 

Bioinformatic processes for determination of peptide binding


This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes..
Iogenetics, Llc


05/12/16
20160131661 

Phosphorylcholine conjugates and corresponding antibodies


In subjects with hypertension, increases in intima-media thickness (imt) at four years were less in subjects also having high autoantibodies particularly igm, to phosphorylcholine. The presence or absence of autoantibodies, particularly igm, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases.
Athera Biotechnologies Ab


05/12/16
20160131656 

Tumor marker, monoclonal antibodies and methods of use thereof


Newly identified proteins as markers for the detection of colon, ovary, kidney, esophagus and prostate tumors, or as therapeutic targets for their treatment; affinity ligands and particularly antibodies capable of selectively interacting with the tumor markers and methods for tumor diagnosis and thereapy using such antibodies.. .
Externautics S.p.a.


05/12/16
20160131653 

Subject anit-hcv antibody detection assays employing ns3 capture peptides


The present disclosure provides methods, kits, and compositions for detecting subject anti-hcv antibodies in a sample using ns3 capture peptides. In certain embodiments, at least two ns3 helicase (ns3h) capture peptides and at least two conjugate peptides (e.g., ns3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step type assay.
Abbott Laboratories




Antibodies topics: Antibodies, Recombinant, Nucleic Acid, Nucleic Acids, Polypeptide, Therapeutics, Immunoglobulin, Immunoglobulins, Monoclonal, Radiation Therapy, Desmoplastic, Hypertension, Hypertensive, Immunotherapy, Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.4935

5076

0 - 1 - 109